# 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

> **NCT01751451** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 124 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone acetate
- **DRUG:** Abiraterone acetate plus degarelix
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT01751451
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-18
- **Primary completion:** 2020-09-28
- **Final completion:** 2020-09-28
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2021-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01751451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01751451, "3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01751451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*